Simulating Destructive and Constructive Morphodynamic Processes in Steep Beaches

Short-term beach morphodynamics are typically modelled solely through storm-induced erosion, disregarding post-storm recovery. Yet, the full cycle of beach profile response is critical to simulating and understanding morphodynamics over longer temporal scales. The XBeach model is calibrated using topographic profiles from a reflective beach (Faro Beach, in S. Portugal) during and after the incidence of a fierce storm (Emma) that impacted the area in early 2018. Recovery in all three profiles showed rapid steepening of the beachface and significant recovery of eroded volumes (68–92%) within 45 days after the storm, while berm heights reached 4.5–5 m. Two calibration parameters were used (facua and bermslope), considering two sets of values, one for erosive (Hm0 ≥ 3 m) and one for accretive (Hm0 < 3 m) conditions. A correction of the runup height underestimation by the model in surfbeat mode was necessary to reproduce the measured berm elevation and morphology during recovery. Simulated profiles effectively capture storm erosion, but also berm growth and gradual recovery of the profiles, showing good skill in all three profiles and recovery phases. These experiments will be the basis to formulate event-scale simulations using schematized wave forcing that will allow to calibrate the model for longer-term changes.

Review of the Volume ”Principalele contracte de comerț internațional” [Main International Trade Contracts], Author: Dumitrița Florea, Lumen Publishing House, 2017

"Principalele contracte de comerţ internaţional” [Main International Trade Contracts] is a book written by Dumitrița Florea and published by Lumen Publishing House from Iasi, Romania, a volume that explains and captures in a clear and structured way the various types of existing contracts that are subject to international trade. This paper was published in 2017, a year when international trade experienced a significant recovery, much more synchronized and generalized compared to previous years, which were marked, in various proportions, by the effects of the crisis of 2008-2009. During this period, the main trend identified is the reorientation, with a new force, of business to the international space, considered profitable and promising.

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

Background. Intestinal microbiota restoration can be achieved by complementing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another emerging application of interest is reducing antibiotic resistant genes (ARGs) and organisms (AROs). In this study, we investigated fecal specimens from a multicenter, randomized, double-blind, placebo-controlled phase 2b study of microbiota-based investigational drug RBX2660. Patients were administered either placebo, 1 dose of RBX2660 and 1 placebo, or 2 doses of RBX2660 via enema and longitudinally tracked for changes in their microbiome and antibiotic resistome.Results. All patients exhibited significant recovery of gut microbiome diversity and a decrease of ARG relative abundance during the first 7 days post-treatment. However, the microbiome and resistome shifts towards average configurations from unperturbed individuals were more significant and longer-lasting in RBX2660 recipients compared to placebo. We quantified microbiome and resistome modification by RBX2660 using a novel ‘transplantation index’ metric. We identified taxonomic and metabolic features distinguishing the baseline microbiome of non-transplanted patients and taxa specifically enriched during the process of transplantation. We elucidated the correlation between resistome and taxonomic transplantations and post-treatment dynamics of patient-specific and RBX2660-specific ARGs. Whole genome sequencing of AROs cultured from RBX2660 product and patient samples indicate ARO eradication in patients via RBX2660 administration, but also, to a lesser extent, introduction of RBX2660-derived AROs.Conclusions. Through shotgun metagenomic sequencing, we elucidated the effects of RBX2660 in the microbiome and resistome. Antibiotic discontinuation alone resulted in significant recovery of gut microbial diversity and reduced ARG relative abundance, but RBX2660 administration more rapidly and completely changed the composition of patients’ microbiome, resistome, and ARO colonization by transplanting RBX2660 microbiota into the recipients. Although ARGs and AROs were transmitted through RBX2660, the resistome post-RBX2660 more closely resembled that of the administered product—a proxy for the donor—than an antibiotic perturbed state.Trial registration: NCT02299570. Registered 19 November 2014, https://clinicaltrials.gov/ct2/show/NCT02299570

Reprocessing of Contaminated MGIT 960 Cultures to Improve Availability of Valid Results for Mycobacteria

Optimal recovery of mycobacteria from the contaminated liquid culture is a challenge. While alternative methods have been suggested to reduce the rate of contamination in the BACTEC MGIT 960 system, reprocessing the contaminated liquid culture improves recovery of Mycobacterium tuberculosis. Among 793 MGIT cultures raised from as many sputum specimens after primary decontamination by the standard NaLC-NaOH method, valid results were available for 687 (86.6%) as 106 (13.4%) were contaminated. Reprocessing and reculturing of the contaminated cultures increased valid results to 739 (93.2%) and reduced the contamination rate to 6.8%. Both values were statistically significant. Recovery of the Mycobacterium tuberculosis complex increased from 45.6% to 48.4%. Valid negative results were available for an additional 3.4%. The method may be adopted to reduce the rate of contamination and to improve the valid culture results for mycobacteria.

The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

Background. Intestinal microbiota restoration can be achieved by replacing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another emerging application of interest is depletion of antibiotic resistant genes (ARGs) and organisms (AROs). In this study, we investigated fecal specimens from a multicenter, randomized, double-blind, placebo-controlled phase 2b study of microbiota-based investigational drug RBX2660. Patients were administered either placebo, 1 dose of RBX2660 and 1 placebo, or 2 doses of RBX2660 via enema and longitudinally tracked for changes in their microbiome and antibiotic resistome. Results. All patients exhibited significant recovery of gut microbiome diversity and a decrease of ARG abundance during the first 7 days post-treatment. However, the microbiome and resistome shifts towards healthier configurations were more significant and longer-lasting in RBX2660 recipients compared to placebo. We quantified microbiome and resistome modification by RBX2660 using a novel ‘transplantation index’ metric. We identified taxonomic and metabolic features distinguishing the baseline microbiome of non-transplanted patients and taxa specifically enriched during the process of transplantation. We elucidated the correlation between resistome and taxonomic transplantations and post-treatment dynamics of patient-specific and RBX2660-specific ARGs. Whole genome sequencing of AROs cultured from RBX2660 product and patient samples indicate ARO eradication in patients via RBX2660 administration, but also, to a lesser extent, introduction of RBX2660-derived AROs. Conclusions. Through shotgun metagenomic sequencing, we elucidated the effects of RBX2660 in the microbiome and resistome. Antibiotic discontinuation alone resulted in significant recovery of gut microbial diversity and reduced ARG abundance, but RBX2660 administration more rapidly and completely changed the composition of patients’ microbiome, resistome, and ARO colonization by transplanting RBX2660 microbiota into the recipients. Although ARGs and AROs were transmitted through RBX2660, the resistome post-RBX2660 more closely resembled that of the administered product—a proxy for the donor—than an antibiotic perturbed state.

The effect of microbiota-based investigational drug RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

Background Intestinal microbiota restoration can be achieved by replacing a subject’s perturbed microbiota with that of a healthy donor. Recurrent Clostridioides difficile infection (rCDI) is one key application of such treatment. Another application of interest is depletion of antibiotic resistant genes (ARGs) and organisms (AROs). In this study, we investigated fecal specimens from a multicenter, randomized, double-blind, placebo-controlled phase 2b study of microbiota-based investigational drug RBX2660. Patients were administered either placebo, 1 dose of RBX2660 and 1 placebo, or 2 doses of RBX2660 via enema and longitudinally tracked for changes in their microbiome and antibiotic resistome. Results All patients exhibited significant recovery of gut microbiome diversity and decrease of ARG abundance during the first 7 days post-treatment. However, the microbiome and resistome shifts towards healthier configurations were more significant and longer lasting in RBX2660 recipients compared to placebo. We identified 18 taxa and 21 metabolic functions distinguishing the baseline microbiome of non-transplanted patients, and the majority of features were correlated to intrinsic vancomycin resistance. We also identified 7 patient-specific and 3 RBX2660-specific ARGs and tracked their dynamics post treatment. Whole genome sequencing of AROs cultured from RBX2660 product and patient samples indicate ARO eradication in patients via RBX2660 administration, but also, to a lesser extent, introduction of RBX2660-derived AROs. Conclusions By including a placebo group, we distinguished the effects of RBX2660 from baseline post-antibiotic microbiome dynamics. Antibiotic discontinuation alone resulted in significant recovery of gut microbial diversity and reduced ARG abundance, but RBX2660 administration more rapidly and completely changed the composition of patients’ microbiome, resistome, and ARO colonization by transplanting RBX2660 microbiota into the recipients. Although ARGs and AROs were transmitted through RBX2660, the resistome post-RBX2660 more closely resembled that of the administered product—a proxy for the donor—than an antibiotic perturbed state.

DYNAMICS OF FORMATION OF TAX REVENUES TO CONSOLIDATED BUDGETS OF CONSTITUENT ENTITIES OF THE RUSSIAN FEDERATION

The article deals with the formation of economic policies aimed at improving the quality and standard of living of the population and general socio-economic development. In 2018-2019 there was a significant recovery of business activity, as a result of which revenues of consolidated budgets of the constituent entities of the Russian Federation increased. The level of property taxes paid by individuals has increased particularly significantly. Against the background of the decline in real incomes of citizens, there was an increase in the tax burden.

Non-surgical approach towards uterine fibroid and ovarian cyst with Yoga practice

A case of a 43 years old female with uterine fibroid and ovarian cyst was managed by an alternative, Non-surgical approach of yoga intervention. Yoga was practised under supervision daily twice a day for three months showed significant recovery from ovarian Cyst and reduction in uterine fibroid size. A diagnosis, where surgery was suggested as the only option, yoga has been found to be effective treatment modality in prevention and management.

Appropriate Timing for Evaluation of the Short-Term Effectiveness of Unicompartmental Knee Arthroplasty

Satisfactory results have been achieved with unicompartmental knee arthroplasty (UKA) for the treatment of isolated unicompartmental knee disease. However, UKA is associated with a significantly higher rate of revision. There is a tendency toward early revision of UKA for persistent pain because surgeons are not aware that outcomes can spontaneously improve with time. The aim of this study was to identify the time period that patients achieved the highest clinical outcomes following UKA. In total, we examined 72 knees that underwent Oxford UKA. We evaluated the range of motion and clinical results including Knee Society Knee Score, Knee Society Function Score (KSFS), and patient-reported scores using the Knee injury and Osteoarthritis Outcome Score (KOOS) at 1, 2, and 3 years postoperatively. The extension angle showed significant recovery from 1 to 2 years postoperatively, but no significant recovery was observed between 2 and 3 years. The flexion angle at 2 years is larger than at 1 year. The KSFS at 3 years is significantly lower than that at 1 year. The KOOS subscale of activities of daily living showed no significant differences among three periods after operation. The subscales of pain, symptom, sports, and quality of life showed significant recovery from 1 to 2 years postoperatively, but no significant recovery was observed from 2 to 3 years. To evaluate the effectiveness of Oxford UKA, surgeons should obtain clinical outcomes 2 years after the operation